| Prior to L-NMMA infusion (at 70 min) | During L-NMMA infusion (at 130 min) |
---|---|---|
PWV(m/s) | ||
 Placebo | 7.5 ± 1.1 | 8.0 ± 1.3* |
 Tolvaptan 60 mg | 7.6 ± 1.3 | 8.2 ± 1.4*** |
 p (paired t-test, between) | 0.598 | 0.501 |
AI (n = 16) | ||
 Placebo | 21.1 ± 7.8 | 23.5 ± 7.3* |
 Tolvaptan 60 mg | 21.1 ± 8.9 | 21.9 ± 9.1 |
 p (paired t-test, between) | 0.949 | 0.130 |
CSBP | ||
 Placebo | 132 ± 11 | 144 ± 18*** |
 Tolvaptan 60 mg | 128 ± 9 | 139 ± 16*** |
 p (paired t-test, between) | 0.084 | 0.124 |
CDBP (n = 17) | ||
 Placebo | 85 ± 9 | 93 ± 10*** |
 Tolvaptan 60 mg | 83 ± 8 | 88 ± 9*** |
 p (paired t-test, between) | 0.142 | 0.004 |